NKT Therapeutics, a Newton, MA-based startup built around technology from Boston’s Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital, announced it has raised $8 million in a Series A financing led jointly by SV Life Sciences and MedImmune Ventures. NKT, whose website says the financing closed in December 2008, is developing treatments for asthma, cancer, autoimmune diseases, and other ailments by targeting natural killer T cells, a type of white blood cell.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
